[A25-125] Upadacitinib (giant cell arteritis) – Addendum to Project A25-66
Last updated 06.11.2025
Project no.:
A25-125
Commission:
Commission awarded on 23.09.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Indication:
Adults with giant cell arteritis
Result of dossier assessment:
- Patients who are candidates for therapy with glucocorticoids alone: unchanged after addendum: added benefit not proven
- Patients who are not candidates for therapy with glucocorticoids alone: unchanged after addendum: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
DOI:
https://doi.org/10.60584/A25-125
| Project no. | Title | Status |
|---|---|---|
| A25-66 | Upadacitinib (giant cell arteritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2025-11-06 A G-BA decision was published.